Boston Scientific Corp. (BSX)


Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

Beginner level

The balance sheet provides creditors, investors, and analysts with information on company’s resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company’s assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Boston Scientific Corp., consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

US$ in millions

Microsoft Excel LibreOffice Calc
Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Current debt obligations 1,297  1,949  1,638  2,253  1,820  1,685  962  1,801  1,266  1,018  64  254  254  253  63  43  423  403 
Accounts payable 512  524  498  349  453  403  404  530  371  376  376  447  298  284  232  209  210  191  228  262  234  241  241 
Accrued expenses 1,932  1,932  1,963  2,246  2,469  2,266  2,447  2,456  2,551  2,238  2,298  2,312  2,099  2,236  1,792  1,970  1,605  1,401  1,512  1,950  1,288  1,277  1,275 
Other current liabilities 513  445  380  412  340  399  1,175  867  640  668  811  764  365  408  331  248  360  302  300  231  295  252  199 
Current liabilities 4,254  4,850  4,479  5,260  5,082  4,753  4,988  5,654  4,828  4,300  3,490  3,587  3,016  3,182  2,608  2,430  2,238  1,937  2,463  2,846  1,820  1,773  1,719 
Long-term debt 9,590  7,591  7,590  4,803  4,806  4,808  4,803  3,815  4,416  4,817  5,509  5,420  5,171  5,173  5,424  5,674  5,796  5,069  3,845  3,859  4,249  4,252  4,245 
Deferred income taxes 807  416  441  328  428  364  128  191  66  58  19  18  26  24  295  735  770  899  963  1,214  1,224  1,302  1,439 
Other long-term liabilities 2,406  2,027  2,059  1,882  1,774  1,946  2,253  2,370  1,738  1,972  1,872  2,338  3,002  3,239  2,934  2,974  3,001  2,638  2,700  2,666  2,724  2,606  2,398 
Long-term liabilities 12,803  10,034  10,090  7,013  7,008  7,118  7,184  6,376  6,220  6,847  7,400  7,776  8,199  8,436  8,653  9,383  9,567  8,606  7,508  7,739  8,197  8,160  8,082 
Total liabilities 17,057  14,884  14,569  12,273  12,090  11,871  12,172  12,030  11,048  11,147  10,890  11,363  11,215  11,618  11,261  11,813  11,805  10,543  9,971  10,585  10,017  9,933  9,801 
Preferred stock, $0.01 par value, none issued and outstanding —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  — 
Common stock, $0.01 par value 16  16  16  16  16  16  16  16  16  16  16  16  19  18  16  16  16  16  16  16  16  16  16 
Treasury stock, at cost (1,717) (1,717) (1,717) (1,717) (1,717) (1,717) (1,717) (1,717) (1,717) (1,717) (1,717) (1,717) (1,717) (1,717) (1,717) (1,717) (1,717) (1,717) (1,717) (1,717) (1,717) (1,717) (1,717)
Additional paid-in capital 17,511  17,423  17,375  17,347  17,304  17,231  17,185  17,162  17,125  17,057  17,015  17,014  16,985  16,923  16,848  16,860  16,815  16,764  16,750  16,703  16,681  16,635  16,599 
Accumulated deficit (6,249) (6,375) (6,528) (6,953) (7,339) (7,770) (8,326) (8,390) (7,785) (8,068) (8,215) (8,581) (8,706) (8,934) (8,725) (8,927) (8,785) (8,587) (8,690) (8,689) (8,389) (8,432) (8,436)
Accumulated other comprehensive income (loss), net of tax 138  78  87  33  25  (16) (128) (59) (51) (53) (46) (99) (70) 35  88  81  104  142  144  110  42  72 
Stockholders’ equity 9,699  9,425  9,233  8,726  8,289  7,744  7,030  7,012  7,588  7,235  7,053  6,733  6,482  6,220  6,457  6,320  6,410  6,580  6,501  6,457  6,701  6,544  6,534 
Total liabilities and stockholders’ equity 26,756  24,309  23,802  20,999  20,379  19,615  19,202  19,042  18,636  18,382  17,943  18,096  17,697  17,838  17,718  18,133  18,215  17,123  16,472  17,042  16,718  16,477  16,335 

Based on: 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-07-30), 10-Q (filing date: 2019-04-29), 10-K (filing date: 2019-02-19), 10-Q (filing date: 2018-10-29), 10-Q (filing date: 2018-07-31), 10-Q (filing date: 2018-05-01), 10-K (filing date: 2018-02-20), 10-Q (filing date: 2017-11-02), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-03), 10-K (filing date: 2017-02-23), 10-Q (filing date: 2016-11-03), 10-Q (filing date: 2016-08-03), 10-Q (filing date: 2016-05-04), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-06), 10-Q (filing date: 2015-05-06), 10-K (filing date: 2015-02-25), 10-Q (filing date: 2014-11-05), 10-Q (filing date: 2014-08-06), 10-Q (filing date: 2014-05-08).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Boston Scientific Corp.’s current liabilities increased from Q1 2019 to Q2 2019 but then decreased significantly from Q2 2019 to Q3 2019.
Long-term liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Boston Scientific Corp.’s long-term liabilities decreased from Q1 2019 to Q2 2019 but then increased from Q2 2019 to Q3 2019 exceeding Q1 2019 level.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Boston Scientific Corp.’s total liabilities increased from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019.
Stockholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity’s stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Boston Scientific Corp.’s stockholders’ equity increased from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019.